Effective September 10, 2020, three non-antiretroviral medications, rosiglitazone, clofazimine, and trimetrexate, have been removed from the ADAP formulary. Rosiglitazone, which is used to treat diabetes, has a black box warning for congestive heart failure and risk of myocardial infarction. Rosiglitazone is not considered a first-line or second-line agent for diabetes and ADAP lists multiple, safer and more effective, oral agents preferred for the treatment of type 2 diabetes. Additionally, utilization of rosiglitazone has been extremely low, with no dispenses occurring in over a year.
ADAP has also removed trimetrexate and clofazimine from the formulary. The manufacturing of trimetrexate was discontinued in 2007 and clofazimine has not been commercially available in the US since 2016.
ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary
has been updated to reflect the removal of rosiglitazone, clofazimine, and trimetrexate. Access to the updated formulary is available at the following URL: https://cdph.magellanrx.com/member/documents
If you have any questions regarding the addition of these medications to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.
Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health